These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
301 related articles for article (PubMed ID: 18830204)
61. Aspirin responsiveness in acute brain ischaemia: association with stroke severity and clinical outcome. Schwammenthal Y; Tsabari R; Shenkman B; Schwartz R; Matetzky S; Lubetsky A; Orion D; Israeli-Korn S; Chapman J; Savion N; Varon D; Tanne D Cerebrovasc Dis; 2008; 25(4):355-61. PubMed ID: 18305387 [TBL] [Abstract][Full Text] [Related]
62. Plasma triglycerides as predictors of platelet responsiveness to aspirin in patients after first ischemic stroke. Karepov V; Tolpina G; Kuliczkowski W; Serebruany V Cerebrovasc Dis; 2008; 26(3):272-6. PubMed ID: 18648200 [TBL] [Abstract][Full Text] [Related]
64. Aprotinin reduces the antiplatelet effect of clopidogrel. Lindvall G; Sartipy U; Bjessmo S; Svenarud P; Lindvall B; van der Linden J Interact Cardiovasc Thorac Surg; 2009 Aug; 9(2):178-81. PubMed ID: 19477870 [TBL] [Abstract][Full Text] [Related]
65. Optical platelet aggregometry does not appear useful as a means of assessing the risk of recurrent vascular events in aspirin-treated patients. Sztriha LK; Sas K; Seres E; Boda K; Lenti L; Csifcsak G; Kovacs N; Vecsei L Acta Neurol Scand; 2008 Apr; 117(4):250-4. PubMed ID: 17961197 [TBL] [Abstract][Full Text] [Related]
66. Changes in platelet P-selectin and in plasma C-reactive protein in acute atherosclerotic ischemic stroke treated with a loading dose of clopidogrel. Cha JK; Jeong MH; Lee KM; Bae HR; Lim YJ; Park KW; Cheon SM J Thromb Thrombolysis; 2002 Oct; 14(2):145-50. PubMed ID: 12714834 [TBL] [Abstract][Full Text] [Related]
67. Nonresponders to clopidogrel therapy among Indian patients undergoing elective/adhoc angioplasty. Thomson VS; John B; Pati PK; George OK; George PV; Jose J Indian Heart J; 2008; 60(6):543-7. PubMed ID: 19276493 [TBL] [Abstract][Full Text] [Related]
68. The curative effect comparison of two kinds of therapeutic regimens on decreasing the relative intensity of microembolic signal in CLAIR trial. Deng QQ; Tang J; Chen C; Markus H; Huang YN; Zhao H; Ratanakorn D; Wong KS; Fu JH J Neurol Sci; 2016 Aug; 367():18-21. PubMed ID: 27423556 [TBL] [Abstract][Full Text] [Related]
69. [Platelet-function inhibitors in the secondary prevention of ischemic stroke]. Busse O; Diener HC; Grond M Dtsch Med Wochenschr; 2006 Nov; 131 Suppl 5():S132-4. PubMed ID: 17089258 [No Abstract] [Full Text] [Related]
70. Facts and controversies of aspirin and clopidogrel therapy. Faxon DP; Freedman JE Am Heart J; 2009 Mar; 157(3):412-22. PubMed ID: 19249409 [TBL] [Abstract][Full Text] [Related]
71. Clinical outcomes of patients with diabetic nephropathy randomized to clopidogrel plus aspirin versus aspirin alone (a post hoc analysis of the clopidogrel for high atherothrombotic risk and ischemic stabilization, management, and avoidance [CHARISMA] trial). Dasgupta A; Steinhubl SR; Bhatt DL; Berger PB; Shao M; Mak KH; Fox KA; Montalescot G; Weber MA; Haffner SM; Dimas AP; Steg PG; Topol EJ; Am J Cardiol; 2009 May; 103(10):1359-63. PubMed ID: 19427428 [TBL] [Abstract][Full Text] [Related]
74. Aspirin and clopidogrel for prevention of ischemic stroke. Thomson RM; Anderson DC Curr Neurol Neurosci Rep; 2013 Feb; 13(2):327. PubMed ID: 23299823 [TBL] [Abstract][Full Text] [Related]
75. Prevalence and risk factors for aspirin and clopidogrel resistance in patients with coronary artery disease or ischemic cerebrovascular disease. Kim H; Lee HK; Han K; Jeon HK Ann Clin Lab Sci; 2009; 39(3):289-94. PubMed ID: 19667414 [TBL] [Abstract][Full Text] [Related]
76. Sildenafil treatment of subacute ischemic stroke: a safety study at 25-mg daily for 2 weeks. Silver B; McCarthy S; Lu M; Mitsias P; Russman AN; Katramados A; Morris DC; Lewandowski CA; Chopp M J Stroke Cerebrovasc Dis; 2009; 18(5):381-3. PubMed ID: 19717023 [TBL] [Abstract][Full Text] [Related]
77. Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial. James S; Akerblom A; Cannon CP; Emanuelsson H; Husted S; Katus H; Skene A; Steg PG; Storey RF; Harrington R; Becker R; Wallentin L Am Heart J; 2009 Apr; 157(4):599-605. PubMed ID: 19332184 [TBL] [Abstract][Full Text] [Related]
78. Temporal trends and patterns of early clopidogrel use across the spectrum of acute coronary syndromes. Rao RV; Goodman SG; Yan RT; Spencer FA; Fox KA; DeYoung JP; Rose B; Grondin FR; Gallo R; Gore JM; Yan AT; Am Heart J; 2009 Apr; 157(4):642-50.e1. PubMed ID: 19332190 [TBL] [Abstract][Full Text] [Related]
79. Clopidogrel and ischemic stroke outcomes by smoking status: Smoker's paradox? Zhang Q; Wang Y; Song H; Hou C; Cao Q; Dong K; Huang X; Feng W; Ovbiagele B; Wang M; Ji X J Neurol Sci; 2017 Feb; 373():41-44. PubMed ID: 28131222 [TBL] [Abstract][Full Text] [Related]
80. Antiplatelet treatment in ischemic stroke treatment. Pinto A; Di Raimondo D; Tuttolomondo A; Di Sciacca R; Arnao V; La Placa S; Milio G; Miceli S; Licata G Curr Top Med Chem; 2009; 9(14):1298-316. PubMed ID: 19849660 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]